That all said, if we can convert those four quotes, we have one-third of top-20 pharma's on the books and if they start a complete conversion to our system, that should start to take care of the recurrent income issue and perhaps even get us to cash flow positive stage, with CRs only required for substantial upscaling and infrastructure upgrades.
Definitely worth sitting and watching what happens in 2024.
Ann: Open Briefing, page-17
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BCT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.546M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.23K | 410.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4154304 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 2669097 | 6 |
View Market Depth
| Last trade - 15.50pm 21/08/2024 (20 minute delay) ? |
| BCT (ASX) Chart |